CA2627541C - Oxazole compound and pharmaceutical composition - Google Patents

Oxazole compound and pharmaceutical composition Download PDF

Info

Publication number
CA2627541C
CA2627541C CA2627541A CA2627541A CA2627541C CA 2627541 C CA2627541 C CA 2627541C CA 2627541 A CA2627541 A CA 2627541A CA 2627541 A CA2627541 A CA 2627541A CA 2627541 C CA2627541 C CA 2627541C
Authority
CA
Canada
Prior art keywords
group
oxazol
phenyl
lower alkoxy
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2627541A
Other languages
English (en)
French (fr)
Other versions
CA2627541A1 (en
Inventor
Minoru Okada
Masaya Kato
Norifumi Sato
Tetsuyuki Uno
Hideki Kitagaki
Junpei Haruta
Hidetaka Hiyama
Tomonori Shibata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CA2627541A1 publication Critical patent/CA2627541A1/en
Application granted granted Critical
Publication of CA2627541C publication Critical patent/CA2627541C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2627541A 2005-11-15 2006-11-14 Oxazole compound and pharmaceutical composition Active CA2627541C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005-330590 2005-11-15
JP2005330590 2005-11-15
PCT/JP2006/323066 WO2007058338A2 (en) 2005-11-15 2006-11-14 Oxazole compound and pharmaceutical composition

Publications (2)

Publication Number Publication Date
CA2627541A1 CA2627541A1 (en) 2007-05-24
CA2627541C true CA2627541C (en) 2014-12-30

Family

ID=37879936

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2627541A Active CA2627541C (en) 2005-11-15 2006-11-14 Oxazole compound and pharmaceutical composition

Country Status (23)

Country Link
US (8) USRE46792E1 (US07846941-20101207-C00217.png)
EP (1) EP1954684B1 (US07846941-20101207-C00217.png)
JP (1) JP5305914B2 (US07846941-20101207-C00217.png)
KR (1) KR101439557B1 (US07846941-20101207-C00217.png)
CN (1) CN101309912B (US07846941-20101207-C00217.png)
AR (3) AR057891A1 (US07846941-20101207-C00217.png)
AU (1) AU2006316079B2 (US07846941-20101207-C00217.png)
BR (1) BRPI0618589B8 (US07846941-20101207-C00217.png)
CA (1) CA2627541C (US07846941-20101207-C00217.png)
CY (1) CY1115302T1 (US07846941-20101207-C00217.png)
DK (1) DK1954684T3 (US07846941-20101207-C00217.png)
ES (1) ES2483992T3 (US07846941-20101207-C00217.png)
HK (1) HK1121162A1 (US07846941-20101207-C00217.png)
IL (1) IL191008A (US07846941-20101207-C00217.png)
MY (1) MY153720A (US07846941-20101207-C00217.png)
NO (1) NO341440B1 (US07846941-20101207-C00217.png)
PL (1) PL1954684T3 (US07846941-20101207-C00217.png)
PT (1) PT1954684E (US07846941-20101207-C00217.png)
RU (1) RU2418793C2 (US07846941-20101207-C00217.png)
SI (1) SI1954684T1 (US07846941-20101207-C00217.png)
TW (1) TWI330639B (US07846941-20101207-C00217.png)
WO (1) WO2007058338A2 (US07846941-20101207-C00217.png)
ZA (1) ZA200803758B (US07846941-20101207-C00217.png)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4986927B2 (ja) * 2007-05-14 2012-07-25 大塚製薬株式会社 医薬
EP2959900B1 (en) 2008-06-16 2017-03-08 University of Tennessee Research Foundation Compound for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
GB2465890A (en) * 2008-12-05 2010-06-09 Scynexis Inc 2-Arylazole derivatives as antiprotozoal agents
CN102883607B (zh) 2010-03-01 2015-07-22 Gtx公司 用于治疗癌的化合物
JP5816635B2 (ja) * 2010-03-05 2015-11-18 カリオファーム セラピューティクス，インコーポレイテッド 核輸送調節剤およびその使用
KR101512548B1 (ko) * 2010-03-12 2015-04-15 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
WO2012099807A1 (en) 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
US9428490B2 (en) 2011-07-29 2016-08-30 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
CN106083827B (zh) 2011-07-29 2019-09-17 卡尔约药物治疗公司 含酰肼的核运输调节剂及其用途
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
EP2776395A2 (en) 2011-11-09 2014-09-17 Mylan Laboratories, Limited Process for the preparation of roflumilast
CN104428295B (zh) 2012-05-09 2017-08-08 卡尔约药物治疗公司 核转运调节剂及其应用
CN109912526A (zh) * 2012-08-30 2019-06-21 大塚制药株式会社 制造噁唑化合物的方法
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
US9738624B2 (en) 2013-06-21 2017-08-22 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
CN105085428B (zh) * 2014-04-25 2019-03-22 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
EA201790384A1 (ru) 2014-08-15 2017-08-31 Кариофарм Терапевтикс, Инк. Полиморфы селинексора
TWI689497B (zh) * 2014-09-04 2020-04-01 南北兄弟藥業投資有限公司 芳雜環類衍生物及其在藥物中的應用
CN107530313A (zh) 2015-04-24 2018-01-02 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
CN106188027B (zh) * 2015-09-02 2020-10-20 广东东阳光药业有限公司 芳杂环类衍生物及其在药物中的应用
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
TWI726027B (zh) * 2015-12-28 2021-05-01 日商大塚製藥股份有限公司 軟膏
CN106279138B (zh) * 2015-12-29 2019-03-01 广东东阳光药业有限公司 芳杂环类衍生物及其在药物中的应用
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
KR20200139736A (ko) 2018-04-04 2020-12-14 오츠카 세이야쿠 가부시키가이샤 옥사졸 화합물 결정
WO2022111605A1 (zh) * 2020-11-27 2022-06-02 瑞石生物医药有限公司 芳基或杂芳基取代五元芳杂环化合物及其用途
CN112425610A (zh) * 2021-01-22 2021-03-02 深圳市洛奇机电科技有限公司 一种防治君子兰叶斑病的农药悬浮剂的制备系统及其应用
CN115785014A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 四唑衍生物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735961A (en) 1984-05-07 1988-04-05 Merck & Co., Inc. Oxazoles and thiazoles containing an aminohydroxypropoxyphenyl moiety
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
US20020169173A1 (en) 1993-11-08 2002-11-14 Smithkline Beecham Corporation Oxazoles for treating cytokine mediated diseases
WO1996000218A1 (en) 1994-06-24 1996-01-04 Euro-Celtique, S.A. Compounds for and method of inhibiting phosphodiesterase iv
AUPO156596A0 (en) 1996-08-09 1996-09-05 University Of Sydney, The Synthetic polynucleotides
DE19632549A1 (de) 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
WO1998008830A1 (de) 1996-08-26 1998-03-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazol-derivate als selektive inhibitoren der pde-iv
EP0971709B1 (en) 1996-10-07 2003-05-21 Eli Lilly And Company Novel compounds useful as neuro-protective agents
US6020339A (en) * 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
JP4518587B2 (ja) * 1998-03-09 2010-08-04 興和創薬株式会社 ２−フェニルモルホリン誘導体
WO2003032981A1 (en) 2001-10-16 2003-04-24 Memory Pharmaceuticals Corporation 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
ATE415160T1 (de) 2002-02-25 2008-12-15 Lilly Co Eli Modulatoren von peroxisome proliferator- aktivierten rezeptoren
JP2004203871A (ja) 2002-12-13 2004-07-22 Yamanouchi Pharmaceut Co Ltd 医薬組成物
TW200505913A (en) 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
CN102816130B (zh) 2004-05-17 2015-05-06 大塚制药株式会社 噻唑化合物及其用途
BRPI0513777A (pt) 2004-07-26 2008-05-13 Lilly Co Eli composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo
DE102004051277A1 (de) * 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
EP1866293A1 (en) * 2005-03-31 2007-12-19 UCB Pharma, S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses

Also Published As

Publication number Publication date
KR20080073337A (ko) 2008-08-08
TW200732332A (en) 2007-09-01
AU2006316079B2 (en) 2012-03-29
EP1954684B1 (en) 2014-05-07
ZA200803758B (en) 2009-08-26
US8637559B2 (en) 2014-01-28
WO2007058338A9 (en) 2007-08-30
PL1954684T3 (pl) 2014-10-31
CY1115302T1 (el) 2017-01-04
US20140100226A1 (en) 2014-04-10
IL191008A (en) 2013-10-31
US20170216260A1 (en) 2017-08-03
US20190070151A1 (en) 2019-03-07
KR101439557B1 (ko) 2014-09-11
USRE46792E1 (en) 2018-04-17
AR109007A2 (es) 2018-10-17
US20220265613A1 (en) 2022-08-25
AU2006316079A1 (en) 2007-05-24
US20090221586A1 (en) 2009-09-03
RU2008123839A (ru) 2009-12-27
WO2007058338A3 (en) 2007-07-19
TWI330639B (en) 2010-09-21
WO2007058338A2 (en) 2007-05-24
US20240148699A1 (en) 2024-05-09
ES2483992T3 (es) 2014-08-08
DK1954684T3 (da) 2014-06-30
HK1121162A1 (en) 2009-04-17
SI1954684T1 (sl) 2014-07-31
PT1954684E (pt) 2014-07-17
JP5305914B2 (ja) 2013-10-02
JP2009515872A (ja) 2009-04-16
CA2627541A1 (en) 2007-05-24
NO341440B1 (no) 2017-11-13
AR109006A2 (es) 2018-10-17
BRPI0618589B8 (pt) 2021-05-25
MY153720A (en) 2015-03-13
US20200078340A1 (en) 2020-03-12
RU2418793C2 (ru) 2011-05-20
NO20081930L (no) 2008-06-10
CN101309912A (zh) 2008-11-19
EP1954684A2 (en) 2008-08-13
CN101309912B (zh) 2013-09-25
AR057891A1 (es) 2007-12-26
BRPI0618589A2 (pt) 2012-07-03
BRPI0618589B1 (pt) 2020-11-17

Similar Documents

Publication Publication Date Title
CA2627541C (en) Oxazole compound and pharmaceutical composition
KR0146931B1 (ko) 옥사졸리딘 유도체 및 그의 약학적으로 허용가능한 염
US20210387941A1 (en) Diphenyl-like Compound, Intermediate Thereof, Preparation Method Therefor, Pharmaceutical Composition Thereof And Uses Thereof
EP0207454B1 (en) Isoxazole and furan derivatives, their preparation and use as antiviral agents
US20050165055A1 (en) Novel substituted indoles
US20090054479A1 (en) Fused heterocyclic derivatives as ppar modulators
JP4986927B2 (ja) 医薬
WO2005023777A1 (ja) Ppar活性化化合物及びこれを含有する医薬組成物
JP2013047189A (ja) 新規パラバン酸誘導体及びそれらを有効成分とする医薬
WO2005066136A1 (en) Bicyclic derivatives as ppar modulators
EP1313716B1 (en) Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
EP1313717B1 (en) Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
EP0398179A1 (en) Rhodanine derivatives and pharmaceutical compositions
PT1502590E (pt) Derivados de oximas heterocíclicas, processo para a sua preparação, e sua utilização no tratamento do diabetes de tipo ii

Legal Events

Date Code Title Description
EEER Examination request